PTC Therapeutics, a US-based drugs developer for muscles, has raised $60m from a consortium including healthcare companies Celgene and Novo.
Venture capital firms Brookside Capital Partners Fund, which led the round, Adage Capital Management, Jennison Associates and Longwood Fund invested in PTC for the first time.
Alongside Celgene and Novo as reinvestors in PTC are Investment bank Credit Suisse and fund managers HBM Healthcare Investments, Vulcan Capital, Delphi Ventures and Column Group.
Credit Suisse was sole structuring adviser and lead placement agent to PTC for the transaction, while Wedbush PacGrow Life Sciences was co-placement agent.
In July, PTC raised $30m, following on from $50m in December 2009. Regulatory filings showed PTC raising $24.25m in September 2007and its first round in 2004.